Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Medicine - PROJECT SUMMARY/ABSTRACT The primary goal and laser focus of our conference, CTTACC, is to accelerate and advance the translation of cell therapies, regenerative approaches, and novel blood products in critically ill patients, all of which are the most rapidly developing areas in transfusion medicine and cell therapies. Trauma and critically ill patients suffer from severe morbidity with few therapeutic options. This is the sixth CTTACC conference organized by Dr. Pati and the CTTACC organizing committee. We anticipate 120 to 150 participants from a variety of backgrounds including academia, industry, the FDA, and federal funding agencies. This meeting is presented by the University of California San Francisco, Department of Laboratory Medicine and the UCSF Center for Research in Transfusion Medicine and Cell Therapies (CTMCT). The 2025 conference is unique in that it is also hosted by the Armed Forces Institute of Regenerative Medicine (AIRM) and Colorado State University. The general plan for the agenda is as follows: the first day is structured to focus on topic areas such as cellular therapies and transfusion medicine in acute and chronic trauma and critical care. Topics will include ARDS, spinal cord injury, neurotrauma and cardiac disease. The first day will also include sessions related to the novel discovery of regenerative factors in blood and specific topics in trauma and transfusion medicine. These talks will set the stage for the second day by presenting innovative technologies that are present and available for development. The second day will include a whole half day military health session which will be focused on four principal areas pertaining to strategies for battlefield care of injured soldiers. The four focus areas include 1) novel blood products on the battlefield, 2) rapid diagnostics for injured patients, 3) acute care of organ failure in remote areas, and 4) acute care of neurotrauma on the battlefield and remote settings. The military health session is designed to generate topic areas for future funding and research development. A consensus paper is planned to be written based on the findings from this session. The second day will also include discussion of novel blood products derived from stem cells and novel blood products currently in development. On the second day an afternoon session will focus on advancing the field of cell and gene therapy editing beyond oncological applications. An FDA regulatory session will discuss challenges in the approval of these novel products. On the last day, which is a half day, a federal agency funding panel will be participate in Q&A by participants interested in future funding opportunities. A panel of key journal editors for these topic areas (Transfusion, Stem Cells, Cytotherapy, Journal of Trauma and Journal of Translational Med) has been assembled. As in years past, we anticipate this conference will support the advancement of the field of transfusion medicine and cell therapies in trauma and critical care.
